Nature's Sunshine Products, Inc. (NASDAQ:NATR - Get Free Report) major shareholder Fosun Pharmaceutical Shanghai sold 2,854,607 shares of the company's stock in a transaction on Friday, June 27th. The stock was sold at an average price of $11.46, for a total transaction of $32,713,796.22. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Nature's Sunshine Products Price Performance
NATR stock traded up $0.29 on Monday, reaching $14.79. 120,567 shares of the company were exchanged, compared to its average volume of 50,532. The firm has a market capitalization of $273.02 million, a PE ratio of 27.91 and a beta of 1.16. Nature's Sunshine Products, Inc. has a 12 month low of $10.81 and a 12 month high of $18.06. The stock's fifty day moving average price is $13.98 and its 200 day moving average price is $13.88.
Nature's Sunshine Products (NASDAQ:NATR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.09. The company had revenue of $113.25 million for the quarter, compared to the consensus estimate of $109.39 million. Nature's Sunshine Products had a net margin of 2.22% and a return on equity of 6.98%.
Analyst Ratings Changes
Separately, DA Davidson reissued a "buy" rating and set a $19.00 price objective on shares of Nature's Sunshine Products in a research report on Tuesday, June 3rd.
Check Out Our Latest Report on Nature's Sunshine Products
Institutional Investors Weigh In On Nature's Sunshine Products
A number of institutional investors have recently added to or reduced their stakes in NATR. Proficio Capital Partners LLC acquired a new stake in Nature's Sunshine Products in the 4th quarter valued at $200,000. Bailard Inc. bought a new position in shares of Nature's Sunshine Products during the fourth quarter valued at $302,000. Amundi acquired a new stake in shares of Nature's Sunshine Products in the 4th quarter valued at $63,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Nature's Sunshine Products in the 4th quarter valued at $314,000. Finally, American Century Companies Inc. grew its holdings in shares of Nature's Sunshine Products by 2.7% in the 4th quarter. American Century Companies Inc. now owns 304,432 shares of the company's stock worth $4,463,000 after purchasing an additional 8,085 shares during the last quarter. 79.40% of the stock is owned by institutional investors and hedge funds.
About Nature's Sunshine Products
(
Get Free Report)
Nature's Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.
Featured Articles
Before you consider Nature's Sunshine Products, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nature's Sunshine Products wasn't on the list.
While Nature's Sunshine Products currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
